0001209191-20-054221.txt : 20201007
0001209191-20-054221.hdr.sgml : 20201007
20201007190009
ACCESSION NUMBER: 0001209191-20-054221
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201006
FILED AS OF DATE: 20201007
DATE AS OF CHANGE: 20201007
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BALDO LANCE
CENTRAL INDEX KEY: 0001780773
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38957
FILM NUMBER: 201229857
MAIL ADDRESS:
STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
STREET 2: 1551 EASTLAKE AVE E STE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp
CENTRAL INDEX KEY: 0001478320
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 270907024
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-659-0067
MAIL ADDRESS:
STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: Adaptive TCR Corp
DATE OF NAME CHANGE: 20091209
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-10-06
0
0001478320
Adaptive Biotechnologies Corp
ADPT
0001780773
BALDO LANCE
C/O ADAPTIVE BIOTECHNOLOGIES CORP.
SUITE 200
SEATTLE
WA
98102
0
1
0
0
Chief Medical Officer
Common Stock
2020-10-06
4
M
0
6250
7.80
A
6250
D
Common Stock
2020-10-06
4
S
0
4236
48.90
D
2014
D
Common Stock
2020-10-06
4
S
0
2014
49.84
D
0
D
Stock Option (Right to Buy)
7.80
2020-10-06
4
M
0
6250
0.00
D
2029-05-06
Common Stock
6250
393750
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.44 to 49.39, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $49.47 to 50.065, inclusive.
The options vested with respect to 1/4 of the shares on May 6, 2020, with 1/48 of the shares vesting thereafter at the end of each full month of continuous service until fully vested.
/s/ Lance Baldo by Eric L. Billings, attorney-in-fact
2020-10-07